You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

VEGFR

Showing 1 - 25 of 911
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Camrelizumab (anti-PD-1 inhibitor), Apatinib

Recruiting
  • Oral Squamous Cell Carcinoma
  • +3 more
  • Camrelizumab (anti-PD-1 inhibitor)
  • Apatinib (anti-VEGFR inhibitor)
  • Shanghai, Shanghai, China
    Ninth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022

Sarcoma Trial in Shanghai (Apatinib monotherapy)

Recruiting
  • Sarcoma
  • Apatinib monotherapy
  • Shanghai, Shanghai, China
    Ruijin Hospital Shanghai Jiao Tong University School of Medicine
May 18, 2022

Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises Trial in Chengdu (Dual-targeting VEGFR1 and PD-L1

Not yet recruiting
  • Malignant Peritoneal Effusion
  • +2 more
  • Dual-targeting VEGFR1 and PD-L1 CAR-T cells
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Jul 26, 2022

Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

Recruiting
  • Chordoma
  • Chemotherapy Effect
  • camrelizumab and apatinib
  • Beijing, Beijing, China
    BEIJING
Nov 14, 2023

Triple-Negative Breast Cancer Trial in Shanghai (VEGFR, nab-paclitaxel, Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin)

Recruiting
  • Triple-Negative Breast Cancer
  • VEGFR
  • +2 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Mar 28, 2023

Nephrotoxicity Trial (Huaier Granule, VEGFR-TKIs)

Not yet recruiting
  • Nephrotoxicity
  • (no location specified)
Jan 5, 2023

Triple-negative Breast Cancer Trial in Shanghai (Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or

Recruiting
  • Triple-negative Breast Cancer
  • Pyrotinib with Capecitabine
  • +6 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 8, 2022

PD-1 Immunotherapy, VEGFR-TKI, Sarcomatoid Carcinoma Trial in Shanghai (Camrelizumab Combined With Apatinib)

Recruiting
  • PD-1 Immunotherapy
  • +3 more
  • Camrelizumab Combined With Apatinib
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Mar 1, 2022

Refractory Soft Tissue Sarcomas Trial run by the NCI (Cabozantinib)

Active, not recruiting
Has Results
  • Refractory Soft Tissue Sarcomas
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Dec 5, 2022

Metastatic Colorectal Cancer, mCRC Trial in Guangzhou (Tislelizumab & Fruquintinib)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • mCRC
  • Tislelizumab & Fruquintinib
  • Guangzhou, Guangdong, China
  • +1 more
Jan 25, 2023

Progress Free Survival (PFS) and Overall Survival (OS) Trial in Guangzhou (Bevacizumab Injection, Nivolumab)

Completed
  • Progress Free Survival (PFS) and Overall Survival (OS)
  • Guangzhou, Guangdong, China
    Fuda Cnacer Hospital
Sep 1, 2021

Metastatic Renal Cell Carcinoma, Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score Trial in France

Not yet recruiting
  • Metastatic Renal Cell Carcinoma
  • Good or Only One Adverse Prognostic Factor Intermediate Risk Per IMDC Score
  • Combination PD-1/PD-L1 ICI + VEGFR-TKI
  • Treatment pause
  • Bayonne, France
  • +24 more
Aug 10, 2022

Clear Cell Renal Cell Carcinoma?Resistance to Immunotherapy Trial in Shanghai (AK104(anti-PD-1/CTLA-4 bi-specific antibody

Recruiting
  • Clear Cell Renal Cell Carcinoma、Resistance to Immunotherapy
  • AK104（anti-PD-1/CTLA-4 bi-specific antibody ，intravenously）,lenvatinib（ targeted VEGFR 1-3、FGFR、PDGFRα， small molecule TKI，orally
  • Shanghai, Shanghai, China
    Shanghai Renji Hospital
Sep 12, 2023

Neovascular Age-related Macular Degeneration, Diabetic Macular Edema Trial in Brisbane (D-4517.2)

Completed
  • Neovascular Age-related Macular Degeneration
  • Diabetic Macular Edema
  • Brisbane, Queensland, Australia
    Nucleus Network (Brisbane)
Sep 19, 2022

Advanced Malignant Tumor, Metastatic Malignant Tumor, Recurrent Malignant Tumor Trial in Houston (Everolimus, Laboratory

Recruiting
  • Advanced Malignant Neoplasm
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 9, 2022

Oral Cancer, VEGFR2 Inhibitor, Programmed Cell Death 1 Inhibitor Trial in Shanghai (drug, procedure, radiation)

Active, not recruiting
  • Oral Cancer
  • +3 more
  • Shanghai, Shanghai, China
    Shanghai Ninth People's Hospital
Jul 23, 2021

Adenocarcinoma, Pancreatic Tumors Trial in Saint Louis, Nashville (X-82, Everolimus)

Terminated
Has Results
  • Adenocarcinoma
  • Pancreatic Neoplasms
  • Saint Louis, Missouri
  • +1 more
Jun 15, 2021

Circulating Tumor DNA-Guided Late-Line Treatment in Late-Stage

Completed
  • Metastatic Breast Cancer
  • +2 more
  • Control group
  • Case group
  • (no location specified)
Jun 16, 2022

Locally Advanced NSCLC Trial in Beijing (Camrelizumab, PD-1 mAb, Apatinib, VEGFR2 antibody)

Recruiting
  • Locally Advanced Non-Small Cell Lung Cancer
  • Camrelizumab, PD-1 monoclonal antibody
  • Apatinib, VEGFR2 antibody
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Aug 15, 2022

Hand-Foot Skin Reaction (HFSR) Trial in United States (OQL011, Vehicle Ointment)

Recruiting
  • Hand-Foot Skin Reaction (HFSR)
  • Whittier, California
  • +32 more
Jan 16, 2023

Breast Cancer, Triple-Negative Breast Cancer Trial in Guangzhou, Nanjing, Shanghai (Anti-PD-1 mAb, VEGFR2 Tyrosine Kinase

Recruiting
  • Breast Cancer
  • Triple-Negative Breast Cancer
  • Anti-PD-1 monoclonal antibody
  • VEGFR2 Tyrosine Kinase Inhibitor
  • Guangzhou, Guangdong, China
  • +2 more
Sep 24, 2022

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (Chemotherapy, Pembrolizumab, Ramucirumab)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • (no location specified)
Jan 9, 2023

Solitary Fibrous Tumor Trial in Milan (Axitinib)

Completed
  • Solitary Fibrous Tumor
  • Milan, MI, Italy
    Fondazione IRCCS Istituto Naazionale dei Tumori
Sep 22, 2021

Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)

Not yet recruiting
  • Recurrent Lung Non-Small Cell Carcinoma
  • Stage IV Lung Cancer AJCC v8
  • Biospecimen Collection
  • +5 more
  • (no location specified)
Sep 7, 2023

NSCLC Trial (Recombinant anti-VEGFR2 fully human mAb (JY025))

Not yet recruiting
  • NSCLC
  • Recombinant anti-VEGFR2 fully human monoclonal antibody (JY025)
  • (no location specified)
May 7, 2021